$1.34
2.19% day before yesterday
Nasdaq, Sep 06, 10:11 pm CET
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Immunic, Inc. Stock price

$1.34
+0.07 5.51% 1M
-0.13 8.84% 6M
-0.16 10.67% YTD
-0.26 16.25% 1Y
-8.76 86.73% 3Y
-12.45 90.28% 5Y
-909.86 99.85% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.03 2.19%
ISIN
US4525EP1011
Symbol
IMUX
Sector
Industry

Key metrics

Market capitalization $120.71m
Enterprise Value $41.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.90
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-93.65m
Free Cash Flow (TTM) Free Cash Flow $-72.76m
Cash position $79.70m
EPS (TTM) EPS $-1.51
P/E forward negative
Short interest 2.82%
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Immunic, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Immunic, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.11 0.11
22% 22%
-
-0.11 -0.11
22% 22%
-
- Selling and Administrative Expenses 17 17
14% 14%
-
- Research and Development Expense 76 76
6% 6%
-
-94 -94
3% 3%
-
- Depreciation and Amortization 0.11 0.11
22% 22%
-
EBIT (Operating Income) EBIT -94 -94
3% 3%
-
Net Profit -95 -95
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Positive
Proactive Investors
about 11 hours ago
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the company's lead compound vidofludimus calcium. Vidofludimus calcium is being supplied for an investigator-sponsored Phase 2 clinical trial focused on treating post-COVID syndrome (PCCS).
Positive
Proactive Investors
3 days ago
Immunic Inc (NASDAQ:IMUX) announced that the first patient has been enrolled in an investigator-sponsored Phase 2 trial of its lead asset vidofludimus calcium for post-COVID syndrome. The RAPID_REVIVE study is sponsored by Goethe University Frankfurt, Germany, with funding received via a grant from the German Federal Ministry of Education and Research.
Neutral
PRNewsWire
4 days ago
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID Readouts, Study Designed to Deliver Important Data on the Activity of Vidofludimus Calcium Suppressing Epstein-Barr Virus Reactivation and Related Fatigue Symptoms; Third-Party Research Identified Epstein...
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 77
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today